543500 — Evoq Remedies Income Statement
0.000.00%
- IN₹80.93m
- IN₹78.78m
- IN₹117.57m
Annual income statement for Evoq Remedies, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 100 | 168 | 204 | 40.5 | 118 |
Cost of Revenue | |||||
Gross Profit | 21.7 | 30.1 | 10.6 | 25 | -13.2 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 90.7 | 153 | 241 | 57 | 140 |
Operating Profit | 9.54 | 14.6 | -37.4 | -16.4 | -22.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 9.54 | 14.6 | 22.8 | 6.11 | 1.28 |
Provision for Income Taxes | |||||
Net Income After Taxes | 7.15 | 10.9 | 16.2 | 4.52 | 0.882 |
Net Income Before Extraordinary Items | |||||
Net Income | 7.15 | 10.9 | 16.2 | 4.52 | 0.882 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 7.15 | 10.9 | 16.2 | 4.52 | 0.882 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.526 | 0.802 | 1.19 | 0.333 | 0.04 |
Dividends per Share |